Effect of atrial fibrillation on endovascular thrombectomy for acute ischemic stroke. A meta-analysis of individual patient data from six randomised trials: Results from the HERMES collaboration.

Ischemic stroke atrial fibrillation endovascular thrombectomy large vessel occlusion

Journal

European stroke journal
ISSN: 2396-9881
Titre abrégé: Eur Stroke J
Pays: England
ID NLM: 101688446

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 19 11 2019
accepted: 03 04 2020
entrez: 19 10 2020
pubmed: 20 10 2020
medline: 20 10 2020
Statut: ppublish

Résumé

Atrial fibrillation is an important risk factor for ischemic stroke, and is associated with an increased risk of poor outcome after ischemic stroke. Endovascular thrombectomy is safe and effective in acute ischemic stroke patients with large vessel occlusion of the anterior circulation. This meta-analysis aims to investigate whether there is an interaction between atrial fibrillation and treatment effect of endovascular thrombectomy, and secondarily whether atrial fibrillation is associated with worse outcome in patients with ischemic stroke due to large vessel occlusion. Individual patient data were from six of the recent randomised clinical trials (MR CLEAN, EXTEND-IA, REVASCAT, SWIFT PRIME, ESCAPE, PISTE) in which endovascular thrombectomy plus standard care was compared to standard care alone. Primary outcome measure was the shift on the modified Rankin scale (mRS) at 90 days. Secondary outcomes were functional independence (mRS 0-2) at 90 days, National Institutes of Health Stroke Scale score at 24 h, symptomatic intracranial hemorrhage and mortality at 90 days. The primary effect parameter was the adjusted common odds ratio, estimated with ordinal logistic regression (shift analysis); treatment effect modification of atrial fibrillation was assessed with a multiplicative interaction term. Among 1351 patients, 447 patients had atrial fibrillation, 224 of whom were treated with endovascular thrombectomy. We found no interaction of atrial fibrillation with treatment effect of endovascular thrombectomy for both primary ( We found no interaction of atrial fibrillation on treatment effect of endovascular thrombectomy, and no difference in outcome between large vessel occlusion stroke patients with and without atrial fibrillation.

Sections du résumé

BACKGROUND BACKGROUND
Atrial fibrillation is an important risk factor for ischemic stroke, and is associated with an increased risk of poor outcome after ischemic stroke. Endovascular thrombectomy is safe and effective in acute ischemic stroke patients with large vessel occlusion of the anterior circulation. This meta-analysis aims to investigate whether there is an interaction between atrial fibrillation and treatment effect of endovascular thrombectomy, and secondarily whether atrial fibrillation is associated with worse outcome in patients with ischemic stroke due to large vessel occlusion.
METHODS METHODS
Individual patient data were from six of the recent randomised clinical trials (MR CLEAN, EXTEND-IA, REVASCAT, SWIFT PRIME, ESCAPE, PISTE) in which endovascular thrombectomy plus standard care was compared to standard care alone. Primary outcome measure was the shift on the modified Rankin scale (mRS) at 90 days. Secondary outcomes were functional independence (mRS 0-2) at 90 days, National Institutes of Health Stroke Scale score at 24 h, symptomatic intracranial hemorrhage and mortality at 90 days. The primary effect parameter was the adjusted common odds ratio, estimated with ordinal logistic regression (shift analysis); treatment effect modification of atrial fibrillation was assessed with a multiplicative interaction term.
RESULTS RESULTS
Among 1351 patients, 447 patients had atrial fibrillation, 224 of whom were treated with endovascular thrombectomy. We found no interaction of atrial fibrillation with treatment effect of endovascular thrombectomy for both primary (
CONCLUSION CONCLUSIONS
We found no interaction of atrial fibrillation on treatment effect of endovascular thrombectomy, and no difference in outcome between large vessel occlusion stroke patients with and without atrial fibrillation.

Identifiants

pubmed: 33072878
doi: 10.1177/2396987320923447
pii: 10.1177_2396987320923447
pmc: PMC7538768
doi:

Types de publication

Journal Article

Langues

eng

Pagination

245-251

Informations de copyright

© European Stroke Organisation 2020.

Références

J Neurol Neurosurg Psychiatry. 2017 Jan;88(1):38-44
pubmed: 27756804
Oncotarget. 2017 Aug 11;8(42):72972-72984
pubmed: 29069841
J Neurol. 2010 Jun;257(6):999-1003
pubmed: 20127250
JAMA Neurol. 2017 Mar 1;74(3):268-274
pubmed: 28097310
Stroke. 2016 Jun;47(6):1486-92
pubmed: 27217503
Stroke. 2017 Aug;48(8):2282-2284
pubmed: 28679847
Lancet Neurol. 2016 Oct;15(11):1138-47
pubmed: 27567239
Eur J Neurol. 2017 Jul;24(7):935-943
pubmed: 28493511
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
Arch Neurol. 2011 Nov;68(11):1454-8
pubmed: 22084129
EuroIntervention. 2017 Oct 20;13(8):996-1002
pubmed: 28649948
J Neurol Sci. 2008 Apr 15;267(1-2):57-61
pubmed: 17964602
J Thromb Thrombolysis. 2017 Aug;44(2):203-209
pubmed: 28702769
Ther Adv Neurol Disord. 2017 Mar;10(3):151-160
pubmed: 28344654

Auteurs

J A Smaal (JA)

Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.

I R de Ridder (IR)

Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.

A Heshmatollah (A)

Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

W H van Zwam (WH)

Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.

Dwj Dippel (D)

Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

C B Majoie (CB)

Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands.

S Brown (S)

Altair Biostatistics, St Louis Park, MN, USA.

M Goyal (M)

Department of Radiology, University of Calgary, Foothills Hospital, Calgary, AB, Canada.

Bcv Campbell (B)

Department of Medicine and Neurology, Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.

K W Muir (KW)

Institute of Neuroscience and Psychology, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK.

A M Demchuck (AM)

Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Foothills Hospital, Calgary, AB, Canada.

A Davalos (A)

Department of Neuroscience, University Autònoma de Barcelona, Spain.

T G Jovin (TG)

Stroke Institute, Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

P J Mitchell (PJ)

Department of Radiology, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.

P White (P)

Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.

J L Saver (JL)

Department of Neurology, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands.

M D Hill (MD)

Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Foothills Hospital, Calgary, AB, Canada.

Y B Roos (YB)

Department of Neurology, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands.

A van der Lugt (A)

Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

R J van Oostenbrugge (RJ)

Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.

Classifications MeSH